Eagle Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Eagle Pharmaceuticals (EGRX) PT Trimmed to $92 at Cantor Fitzgerald; Angiomax Announcement Removes Overhang
July 2, 2015 1:09 PM EDTCantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating but trimmed here price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $92.00 (from $95.00). The change follows news that Angiomax patents held by The Medicines Company were invalidated and Eagle management indicated that it now... More
